Continuity Biosciences Invests in PinPrint, Inc., Expanding into Aesthetic and Cosmetic Drug Delivery

Continuity Biosciences Invests in PinPrint, Inc., Expanding into Aesthetic and Cosmetic Drug Delivery

BRADENTON, Fla., April 29, 2025 /PRNewswire/ -- Continuity Biosciences, LLC has made a strategic investment in PinPrint, Inc., a pioneering company in high-resolution 3D-printed microneedle technology. The investment expands Continuity's footprint...

ZTO Express to Hold Annual General Meeting on June 17, 2025

ZTO Express to Hold Annual General Meeting on June 17, 2025

SHANGHAI, April 29, 2025 /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO and HKEX: 2057) ("ZTO" or the "Company"), a leading and fast-growing express delivery company in China, today announced that it will hold its annual general meeting of...

ZTO to Announce First Quarter Financial Results on May 20, 2025 U.S. Eastern Time

ZTO to Announce First Quarter Financial Results on May 20, 2025 U.S. Eastern Time

SHANGHAI, April 29, 2025 /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) ("ZTO" or the "Company"), a leading and fast-growing express delivery company in China, today announced that it will release its unaudited financial...

TDH Holdings, Inc. Reports Full Year 2024 Audited Financial Results

TDH Holdings, Inc. Reports Full Year 2024 Audited Financial Results

BEIJING, April 28, 2025 /PRNewswire/ -- TDH Holdings, Inc. (NASDAQ: PETZ) ("TDH" or the "Company"), a PRC-based company that is an operator and manager of commercial real estate properties, announced today its financial results for the fiscal year...

Safire Awarded $4.5 Million Contract for Advanced Resilient Energy Systems (ARES) Program

Safire Awarded $4.5 Million Contract for Advanced Resilient Energy Systems (ARES) Program

Award Expands Safire's Role as Systems Integrator in Building the Future Electric for Defense Markets KNOXVILLE, Tenn., April 28, 2025 /PRNewswire/ -- Safire Technology Group, Inc. ("Safire"), has been awarded a $4.5 million contract by the U.S. Air...

2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs

2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...

Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab

Ivonescimab Receives NMPA Approval for First-Line Treatment of PD-L1-Positive NSCLC, Based on Breakthrough Head to Head Phase III Trial Demonstrating Superior Efficacy Over Pembrolizumab

HONG KONG, April 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that its globally first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has received approval from the National Medical Products...

ReTo Eco-Solutions, Inc. Announces Acquisition of Majority Interest in MeinMalzeBier Holdings Limited

ReTo Eco-Solutions, Inc. Announces Acquisition of Majority Interest in MeinMalzeBier Holdings Limited

BEIJING, April 25, 2025 /PRNewswire/ -- ReTo Eco-Solutions, Inc. (Nasdaq: RETO) ("ReTo" or the "Company"), a manufacturer of ecological environment protection equipment and intelligent equipment in China, today announced that on April 25, 2025, it...

Autoliv presents Omni Safety at 2025 Shanghai Auto Show

Autoliv presents Omni Safety at 2025 Shanghai Auto Show

SHANGHAI, April 25, 2025 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) and (SSE: ALIVsdb), the worldwide leader in automotive safety systems, presented Omni Safety ™ , at the Shanghai International Automobile Industry Exhibition 2025. Omni Safety ™ is a...

Announcement of Paper Publication: EditForce Demonstrates Efficacy of Treatment for Myotonic Dystrophy Type 1 Using PPR Platform Technology

Announcement of Paper Publication: EditForce Demonstrates Efficacy of Treatment for Myotonic Dystrophy Type 1 Using PPR Platform Technology

FUKUOKA, Japan, April 25, 2025 /PRNewswire/ -- EditForce, Inc. (Headquarters: Fukuoka, Japan) is pleased to announce that a research paper on the results of a joint study with the research group led by Professor Masayuki Nakamori of the Department...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 29
  • menu
    menu